Tracon commences dosing in Phase III trial of TRC105 to treat angiosarcoma

US-based clinical-stage biopharmaceutical firm Tracon Pharmaceuticals has commenced dosing in its Phase III trial of TRC105 in combination with Votrient (pazopanib) for the treatment of angiosarcoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news